M&A / Deals Curium strikes $8bn deal to buy radiopharma rival Lantheus PharmaphorumTwo players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.Read full story pharminent August 3, 2026 (Last updated: August 8, 2026) Pharmaphorum Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Parsortix study shows promise for ADC target detectionNext: Supernus and Indivior merge to create CNS mega-company with 11 approved drugs Related Stories M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026 M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ pharminent August 4, 2026
